Marshall Edwards, Inc. To Present At The CIBC World Markets Annual Biotechnology And Specialty Pharmaceuticals Conference
WASHINGTON, March 31 /PRNewswire-FirstCall/ -- Marshall Edwards, Inc. will be presenting at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference on Tuesday April 4, 2006.
The presentation at the Millennium Broadway, New York City will be at 8.30am and webcast on http://www.veracast.com/webcasts/cibcwm/biotech06/62101372.cfm
About Marshall Edwards:
Marshall Edwards, Inc. has licensed rights from Novogen Limited to bring phenoxodiol to market globally. Marshall Edwards, Inc. is majority owned by Novogen, an Australian biotechnology company that is specializing in the development of therapeutics based on regulation of the sphingomyelin pathway. Novogen, based in Sydney, Australia, is developing a range of therapeutics across the fields of oncology, cardiovascular disease and inflammatory diseases.
Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.
Marshall Edwards, Inc.
CONTACT: David Sheon, +1-202-518-6321, for Marshall Edwards, Inc.